Maintenance treatment with antipsychotic drugs for schizophrenia
Authors:
- 16 May 2012
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 5,p. CD008016
Abstract
The symptoms and signs of schizophrenia have been firmly linked to high levels of dopamine in specific areas of the brain (limbic system). Antipsychotic drugs block the transmission of dopamine in the brain and reduce the acute symptoms of the disorder. This review examined whether antipsychotic drugs are also effective for relapse prevention. To review the effects of maintaining antipsychotic drugs for people with schizophrenia compared to withdrawing these agents. We searched the Cochrane Schizophrenia Group's Specialised Register (November 2008), with additional searches of MEDLINE, EMBASE and clinicaltrials.gov (June 2011). We included all randomised trials comparing maintenance treatment with antipsychotic drugs and placebo for people with schizophrenia or schizophrenia‐like psychoses. We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention‐to‐treat basis based on a random‐effects model. For continuous data, we calculated mean differences (MD) or standardised mean differences (SMD) again based on a random‐effects model. The review currently includes 65 randomised controlled trials (RCTs) and 6493 participants comparing antipsychotic medication with placebo. The trials were published from 1959 to 2011 and their size ranged between 14 and 420 participants. In many studies the methods of randomisation, allocation and blinding were poorly reported. Although this and other potential sources of bias limited the overall quality, the efficacy of antipsychotic drugs for maintenance treatment in schizophrenia was clear. Antipsychotic drugs were significantly more effective than placebo in preventing relapse at seven to 12 months (primary outcome; drug 27%, placebo 64%, 24 RCTs, n=2669, RR 0.40 CI 0.33 to 0.49, number needed to treat for an additional beneficial outcome (NNTB 3 CI 2 to 3). Hospitalisation was also reduced, however, the baseline risk was lower (drug 10%, placebo 26%, 16 RCTs, n=2090, RR 0.38 CI 0.27 to 0.55, NNT 5 CI 4 to 9). More participants in the placebo group than in the antipsychotic drug group left the studies early due to any reason (at 7‐12 months: drug 38%, placebo 66%, 18 RCTs, n=2420, RR 0.55 CI 0.46 to 0.66, NNTB 4 CI 3 to 5) and due to inefficacy of treatment (at 7‐12 months: drug 20%, placebo 50%, 18 RCTs, n=2420, RR 0.36 CI 0.28 to 0.45, NNTB 3 CI 2 to 4). Quality of life was better in drug‐treated participants (3 RCTs, n=527, SMD ‐0.62 CI ‐1.15 to ‐0.09). Conversely, antipsychotic drugs as a group and irrespective of duration, were associated with more participants experiencing movement disorders (e.g. at least one movement disorder: drug 16%, placebo 9%, 22 RCTs, n=3411, RR 1.55 CI 1.25 to 1.93, NNTH 25 CI 13 to 100), sedation (drug 13%, placebo 9%, 10 RCTs, n=146, RR 1.50 CI 1.22 to 1.84, number needed to treat for an additional harmful outcome (NNTH) not significant) and weight gain (drug 10%, placebo 6%, 10 RCTs, n=321, RR 2.07 CI 1.31 to 3.25, NNTH 20 CI 14 to 33). The results of the primary outcome were robust in a number of subgroup, meta‐regression and sensitivity analyses, the main exception being that the drug‐placebo difference in longer trials was smaller than in shorter trials. The results clearly demonstrate the superiority of antipsychotic drugs compared to placebo in preventing relapse. This effect must be weighed against the side effects of antipsychotic drugs. Future studies should focus on outcomes of social participation and clarify the long‐term morbidity and mortality associated with these drugs. Traitement d’entretien avec des médicaments antipsychotiques de la schizophrénie Les symptômes et les signes de la schizophrénie ont été formellement liés à des niveaux élevés de dopamine dans des régions spécifiques du cerveau (système limbique). Les médicaments antipsychotiques bloquent la transmission de dopamine dans le cerveau et réduisent les symptômes aigus du trouble. Cette revue a examiné des médicaments antipsychotiques afin de déterminer s'ils sont également efficaces pour la prévention des rechutes. Évaluer les effets du maintien des médicaments antipsychotiques pour les personnes atteintes de schizophrénie comparé au retrait de ces agents. Nous avons effectué une recherche dans le registre spécialisé du groupe Cochrane sur la schizophrénie (novembre 2008), ainsi que des recherches supplémentaires dans MEDLINE, EMBASE et clinicaltrials.gov (juin 2011). Nous avons inclus tous les essais randomisés comparant le traitement d’entretien à des médicaments antipsychotiques et au placebo chez des personnes atteintes de schizophrénie ou de psychose de type schizophrénique. Nous avons extrait les données de manière indépendante. Pour les variables dichotomiques, nous avons calculé les risques relatifs (RR) et leurs intervalles de confiance (IC) à 95 % en intention de traiter en fonction d'un modèle à effets aléatoires. Pour les variables continues, nous avons calculé les différences moyennes (DM) ou les différences moyennes standardisées (DMS), là aussi en fonction d'un modèle à effets aléatoires. La revue inclut actuellement 65 essais contrôlés randomisés (ECR) et 6 493 participants comparant les médicaments antipsychotiques au placebo. Les essais ont été publiés de 1959 à 2011 et leur taille variait entre 14 et 420 participants. Dans de nombreuses études, les méthodes de randomisation, d'assignation et de mise en aveugle étaient mal rapportées. Bien que cette source de biais et d'autres sources de biais potentielles aient limité la qualité...Keywords
This publication has 174 references indexed in Scilit:
- Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled studySchizophrenia Research, 2010
- Influence of antipsychotics on mortality in schizophrenia: Systematic reviewSchizophrenia Research, 2009
- Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac DeathNew England Journal of Medicine, 2009
- Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetryJournal of Clinical Epidemiology, 2008
- Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophreniaSchizophrenia Research, 2005
- Schizophrenia and employmentSocial Psychiatry and Psychiatric Epidemiology, 2004
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- d-Amphetamine raises serum prolactin in man: Evaluations after chronic placebo, lithium and pimozide treatmentLife Sciences, 1978
- Maintenance Treatment of Schizophrenic Outpatients With a Depot PhenothiazinePsychosomatics, 1968
- Discontinuation or reduction of chemotherapy in chronic schizophrenicsJournal of Chronic Diseases, 1964